Company / Working Capital per Share
Enliven Therapeutics, Inc. Working Capital per Share History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital per Share
$6.42
FY2024
5-year range
$3.95 / $21.78
FY2020-FY2024
Trend
-5.0%
vs FY2023
Sector context
#86 of 210
Health Care
What the data says
At $6.42, Enliven Therapeutics, Inc.'s working capital per share ranks #86 of 210 in the Health Care sector. Declined from $21.78 to $6.42 over the past 2 years.
Based on SEC 10-K filings.
6.42 in FY2024 with a 5-year CAGR of -29.8%.
Declined from $21.78 to $6.42 over the past 2 years.
Health Care sector context is included.
Working Capital per Share over time
Growth rates
- 3-Year CAGR
- +17.6%
- 5-Year CAGR
- -29.8%
- 10-Year CAGR
- -
Sector benchmark
#86 of 210 in Health CareTop 41% of 210This company $6.42 Sector average $118.60
▼
-94.6% below sector average
Key checks
Key Insights
- In FY2024, working capital per share decreased 5.0% year-over-year.
- Ranks #86 out of 210 companies in the Health Care sector.
- Peak working capital per share was recorded in FY2019.
- Lowest working capital per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working Capital per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $6.42 | -5.0% |
| FY2023 | $6.76 | -69.0% |
| FY2022 | $21.78 | +451.8% |
| FY2021 | $3.95 | -34.7% |
| FY2020 | $6.04 | -83.9% |
| FY2019 | $37.62 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026